- Boston Scientific ( NYSE: BSX ) has entered into a collaboration with Truveta , which provides de-identified health data on more than 65M patients, to analyze patient outcomes related to the use of the device company's products.
- The first analysis under the partnership will be on patient outcomes related to the use of Boston Scientific ( BSX ) products indicated for treatment of peripheral artery disease.
- The company noted that the data provided by Truveta will help address the disparities in access to healthcare treatments.
- Seeking Alpha's Quant Rating views Boston Scientific as a hold with high grades for profitability and momentum .
For further details see:
Boston Scientific in partnership with Truveta on patient outcomes to improve care